Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

Crucell Holland BV240 enrolled

Overview

The purpose of this study is to examine the safety and tolerability after administration of trivalent and quadrivalent cell-based virosomal influenza vaccine in healthy adults.

This is a double-blind and randomized study in healthy adults. The duration of study will be approximately 90 days per participant. The study will include 4 visits: Day 1 (for vaccination), Day 4, Day 22 and day 90 (Follow-up visits). Safety and tolerability will be assessed by the rate of solicited, unsolicited, and serious adverse events.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

240

Conditions

Influenza

Interventions

Trivalent virosomal influenza vaccineBIOLOGICAL

Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.

Commercial vaccine 1BIOLOGICAL

Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.

Quadrivalent virosomal influenza vaccineBIOLOGICAL

Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 49 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male or female adults * Body Mass Index \<= 30 kilogram per square meter (kg/m\^2) * Written informed consent Exclusion Criteria: * Vaccination with 2013/2014-seasonal influenza vaccine and/or receipt of any vaccine in the 4 weeks preceding receipt of study vaccine and/or any vaccination planned within 3 weeks from the study vaccine * Diagnosis (by rapid test, performed at clinic/hospital laboratory) of laboratory-confirmed influenza in the 2013/2014 season * Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or other acute disease * Acute febrile illness (greater than or equal to 38.0 celcius) * Pregnancy as assessed by urine pregnancy test before vaccination, or lactation. Women of childbearing potential (that is, not surgically sterilized/hysterectomized or post-menopausal for more than 2 years) will be excluded if one of the following criteria is met: 1). Intention to become pregnant during the course of the study or to donate eggs (ova, oocytes) for the purposes of assisted reproduction 2). If heterosexually active, not using or not willing to continue using a medically reliable method of contraception for the entire study duration (up to 90 days). A medically reliable method of contraception includes oral contraceptive preparation (for example pills), hormonal implant, progestative injection, patch contraceptive formulation, an intrauterine device, concomitant use of barrier method and spermicide, or another method considered sufficiently reliable by the investigator in individual cases

Locations (4)

Unnamed facility

Aalst, Belgium

Unnamed facility

Ghent, Belgium

Unnamed facility

Merksem, Belgium

Unnamed facility

Wilrijk, Belgium

Outcomes

Primary Outcomes

Number of participants with Solicited Local Adverse Events (AEs)

The local AEs pain, erythema, and induration at the study vaccine injection site will be noted in the participant Diary from Day 1 to Day 8. The extent (largest diameter) of any redness or induration should be measured daily and recorded, along with any functional limitation of activity. Local AEs will be graded according to severity as mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4).

Time frame: Up to Day 8

Number of participants with Solicited Systemic Adverse Events (AEs)

The solicited systemic AEs headache, fatigue, myalgia, malaise, and shivering/rigors will be noted in the participant Diary from Day 1 to Day 8. Fever (defined as body temperature greater than 38.0 Celsius) is another solicited systemic AE. Local AEs will be graded according to severity as mild (grade 1), moderate (grade 2), severe (grade 3) and potentially life threatening (grade 4).

Time frame: Up to Day 8

Number of participants with Unsolicited Adverse Events (AEs)

Unsolicited AEs are all AEs the participants are not specifically asked about in the participant Diary.

Time frame: Up to Day 22

Number of participants with Serious Adverse Events (SAEs)

The SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization or is a suspected transmission of any infectious agent via medicinal product.

Time frame: Up to Day 90

Secondary Outcomes

Number of Participants with Seroconversion

Number of participants with seroconversion will be the participants with a greater than or equal to (\>=) 4-fold increase in hemagglutination inhibition (HI) antibody titer and a titer of \>=1:40 at Day 22. HI against homologous strains will be measured with the HI test in serum.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.